Quote:

---

About Amarantus BioScience Holdings, Inc.

Amarantus BioScience Holdings (OTCQX:AMBS) is a biotechnology association building treatments and diagnostics for diseases in a areas of neurology and waif diseases. AMBS’ Therapeutics multiplication has growth rights to eltoprazine, a tiny proton now in a Phase 2b clinical module for Parkinson’s illness levodopa-induced dyskinesia with a intensity to enhance into adult ADHD and Alzheimer’s aggression. The Company has an disdainful worldwide permit to egghead skill rights compared to Engineered Skin Substitute (ESS), an waif drug designated autologous full density skin deputy product in growth for a diagnosis of serious browns now scheming to enter Phase 2 clinical studies. AMBS owns a egghead skill rights to a healing protein famous as mesencephalic-astrocyte-derived neurotrophic means (MANF) and is building MANF as a diagnosis for waif ophthalmic disorders, primarily in retinitis pigmentosa (RP). AMBS also owns a find of neurotrophic factors (PhenoGuard™) that led to MANF’s discovery.

AMBS’ Diagnostics multiplication owns a rights to MSPrecise®, a disdainful next-generation DNA sequencing (NGS) exam for a marker of patients with relapsing-remitting mixed sclerosis (RRMS), and has an disdainful worldwide permit to a Lymphocyte Proliferation exam (LymPro Test®) for Alzheimer’s disease, that was grown by Prof. Thomas Arendt, Ph.D., from a University of Leipzig, and owns serve egghead skill for a diagnosis of Parkinson’s illness (NuroPro®).

---